The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Science from our Sisters

Science from our Sisters

November 1, 2006 • By Norra MacReady

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Arthritis & Rheumatism

Long-Term Benefits of Induction Therapy for GCA

Induction therapy with high intravenous doses of methylprednisolone suppresses inflammation and hastens remission in patients with giant cell arteritis (GCA), according to a new study in Arthritis & Rheumatism (2006;54(10):3310-3318).

You Might Also Like
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
Explore This Issue
November 2006
Also By This Author
  • Science from our Sisters

Perhaps the most important finding was that the induction therapy had long-term benefits with a higher frequency of patients in sustained remission off treatment and less smoldering disease after one year, senior author Jorg J. Goronzy, MD, PhD, professor of medicine at Emory University School of Medicine in Atlanta, tells The Rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, 27 patients with biopsy-proven GCA were randomized to receive daily infusions of methylprednisolone in a dose of 15 mg/kg or a saline placebo for three days. All patients also took oral prednisone, starting with a dose of 40 mg/day and tapering as long as disease activity was controlled. After the infusions, the patients were followed every four weeks by physicians who were blinded to each patient’s infusion status. They reported their findings at 36, 52, and 78 weeks after the start of therapy.

For all patients, the mean erythrocyte sedimentation rate and C-reactive protein values returned to normal by the first four-week follow-up visit. This was unexpected, given that the doses were lower than those conventionally recommended, says Dr. Goronzy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This suggests that patients without evidence of severe vascular manifestations could do well initially with a lower dose and more rapid tapering of prednisone. However, without methylprednisolone induction therapy, the disease may smolder and require a higher cumulative dose of oral prednisone to keep it under control, says lead author Mehrdad Mazlumzadeh, MD, assistant professor of medicine at the Mayo Clinic in Scottsdale, Ariz.

Ten of the 14 patients (71%) who received methylprednisolone achieved the primary outcome of staying in remission at 36 weeks on oral prednisone in doses of 5 mg/day or less, compared with only two of the 13 (15%) control patients (p=0.003). Six patients in the methylprednisolone group were off treatment entirely by the three-week point, compared with none of the control patients.

What’s more, patients who received the methylprednisolone required much lower median doses of oral glucocorticoids at every follow-up period. Over the length of the study, they took a median of 5,636 mg of prednisone, compared to a cumulative median of 7,860 mg taken by patients in the control group (p=0.001). The relapse rate was also significantly lower among patients in the IV glucocorticoid group, although there was no significant difference in the rate of adverse effects.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Research Reviews, Vasculitis Tagged With: A&R, AC&R, Exercise, Giant Cell Arteritis, hip arthroplasty, Journals, knee arthroplasty, Literature, Methylprednisolone, prednisoneIssue: November 2006

You Might Also Like:
  • Science from our Sisters
  • Science from our Sisters
  • Science from our Sisters
  • Science From Our Sisters

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)